Press releases
- Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- Neurocrine Biosciences to Participate at Investor Conferences in June
- Neurocrine Biosciences Announces CEO Succession Plan
- Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
- Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
More ▼
Key statistics
As of last trade Neurocrine Biosciences Inc (NB3:STU) traded at 121.25, -13.02% below its 52-week high of 139.40, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 121.25 |
---|---|
High | 121.25 |
Low | 121.25 |
Bid | 124.25 |
Offer | 125.95 |
Previous close | 120.45 |
Average volume | 0.00 |
---|---|
Shares outstanding | 100.64m |
Free float | 98.82m |
P/E (TTM) | 36.74 |
Market cap | 13.45bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼